Researchers at Adnan Menderes University set out to determine the microRNA (miRNA) expression profiles of neuroblastomas with different clinical and histological characteristics. In this study, the researchers utilized miRNA microarray technology to compare the miRNA profiles of 24 FFPE samples from 17 patients.

They found that 25 miRNAs between well-poorly differentiated tumors, eight miRNAs before and after of the chemotherapy, three miRNAs between favorable and unfavorable histology, four miRNAs between neuroblastoma and ganglioneuroma, seven miRNAs between low and middle risk, one miRNA between middle and high risk, 14 miRNAs between low and high risk were differently expressed. KEGG pathway analysis revealed that these miRNAs mainly targeted the cancer pathway. After comparing the clinical data and all microRNAs, the most marked difference was seen in miR-132 and miR-490. The highest fold change was detected in miR-98-5p between the tissues of high- and low-risk patients.

This study provides microRNA expression profiles of neuroblastoma patients’ tissue with different clinical, histological grade, differentiation, and treatment status, which could be informative for new therapies targeting microRNAs.

 

MicroRNA profiles in neuroblastoma: Differences in risk and histology groups  - Ergin - 2018 - Asia-Pacific Journal of Clinical Oncology - Wiley Online  Library

Heat-map of differentially expressed miRNA in comparison of poorly (P)-well (W) differentiated groups (p < 0.01). The analysis shows relative fluorescence from green (2-fold reduction) to red (2-fold increase) of each sample.

 


Related Service

miRNA Microarray Service – LC Sciences provides a microRNA (miRNA) expression profiling service using microarrays based on our in-house developed µParaflo® technology platform. We have standard arrays for all mature miRNAs of all species available in the latest version of the miRBase database (Release 21, July 2014). Our service is comprehensive and includes sample labeling, array hybridization, image data processing and in-depth data analysis. Two-three weeks after receiving your total RNA samples, we’ll send you both the raw and fully analyzed data. [Learn more…]


Reference

K. Ergin, S. Aktaş, Z. Altun, G. Dınız, N. Olgun (2017) MicroRNA profiles in neuroblastoma: Differences in risk and histology groups A-P J. of Clinical Onc. doi: 10.1111/ajco.12821 [abstract]